ICD-10 K29.70: Gastritis Without Bleeding — The Payer-Proof Documentation Playbook for Gastroenterology

Clinical Update — June 2026: This guide has been revised to incorporate the CMS MS-DRG v42.0 classification updates, the 2025 Maastricht VI/Florence Consensus Report addendum on pre-test washout verification, and updated MAC LCD audit triggers for H. pylori UBT and EGD 43239 authorization. Prior-authorization logic, FHIR R4 export schemas, and SNOMED CT body-site mappings have been updated to reflect HL7 FHIR R4 Condition resource changes effective Q1 2026. If you implemented workflows from the prior version of this playbook, review the revised washout documentation table and LCD language templates below.

TL;DR: K29.70 (Gastritis, unspecified, without bleeding) is one of the most frequently coded — and frequently denied — diagnoses in gastroenterology. Most references, including the CMS MS-DRG Definitions Manual, list K29.70 as a principal diagnosis for DRG 391/392 but provide zero guidance on the documentation specificity required to survive payer scrutiny for associated H. pylori testing and EGD biopsy authorization. This playbook closes that gap. It details the three documentation elements that separate a first-pass clean claim from a denial: (1) negation-aware NSAID exposure capture with time-bounded PPI/antibiotic/bismuth washout documentation, (2) epigastric pain topography normalized to antral vs. fundic body-site granularity, and (3) diagnosis specificity routing from R10.13 to K29.70 to B96.81 that mirrors the clinical decision sequence and avoids premature code assignment. Scribing.io's speech-to-structure pipeline encodes all three into every gastritis note automatically.

Table of Contents

• What Competitors Get Wrong About K29.70: The Documentation-to-Authorization Gap

• Why NSAID Negation and Washout Windows Are Payer-Critical for H. pylori and EGD Authorization

• Scribing.io Clinical Logic: From Denied Claim to First-Pass Payment in Gastritis Workup

• Technical Reference: ICD-10 Documentation Standards for K29.70 and R10.13

• Antral vs. Fundic: Why Body-Site Topography Drives Procedural Authorization

• FHIR R4 Export Architecture: Structured Data That Survives Payer Adjudication

• Diagnosis Routing Sequence: R10.13 → K29.70 → B96.81

• LCD-Ready Language Templates for EGD 43239

• Gastritis/H. pylori Denial-Prevention Pack

What Competitors Get Wrong About K29.70: The Documentation-to-Authorization Gap

The standard reference for K29.70 — exemplified by the CMS MS-DRG v42.0 Definitions Manual — accomplishes one task well: it places K29.70 — Gastritis, unspecified, without bleeding; R10.13 — Epigastric pain into DRG 391/392 groupings. It tells you that K29.70 is a valid principal diagnosis. It does not tell you how to document the note so that the downstream H. pylori urea breath test (UBT) is medically necessary, the EGD with biopsy (CPT 43239) clears prior authorization, and the claim pays on first submission.

This is not a trivial omission. It is the central failure point in gastritis revenue cycle performance. Scribing.io exists to close precisely this gap — the space between a valid ICD-10 classification and a defensible, payer-proof clinical note.

Current clinical benchmarks from the American Journal of Gastroenterology and internal denial-pattern analyses across multi-site GI practices indicate that H. pylori UBT denial rates climb sharply when the ordering note contains any of the following documentation deficiencies:

• Unspecified abdominal pain (R10.9) instead of epigastric pain (R10.13) as the supporting symptom code — stripping anatomic specificity that justifies upper GI workup over colonoscopy or CT abdomen

• No statement regarding NSAID exposure, leaving the payer unable to distinguish NSAID gastropathy (which does not warrant H. pylori testing as first-line per ACG Clinical Guidelines) from non-NSAID dyspepsia (which does)

• No documentation of PPI/antibiotic/bismuth washout, rendering H. pylori test results clinically unreliable and giving payers grounds to deny both the test and any subsequent EGD predicated on its results

The CMS DRG reference contains none of this operational intelligence. It is a classification table, not a documentation standard. Every coding site you have bookmarked reproduces the same table. The gap between "K29.70 is in DRG 392" and "here is the note language that gets K29.70-associated procedures paid" is where the Scribing.io ICD-10 Documentation Library operates — and where competitors remain silent.

Why NSAID Negation and Washout Windows Are Payer-Critical for H. pylori and EGD Authorization

The American College of Gastroenterology (ACG) and the Maastricht VI/Florence Consensus Report (2022, updated 2025) establish a clear clinical decision fork at the point of NSAID exposure assessment. If the patient is actively using NSAIDs, the initial management pathway diverges: NSAID cessation and PPI therapy take precedence, and H. pylori testing may be deferred or interpreted differently. Payers — including CMS, UnitedHealthcare, and Aetna — have operationalized this fork into Local Coverage Determinations (LCDs) and proprietary medical review criteria.

The Three Washout Windows Payers Audit

When H. pylori testing (UBT or stool antigen) is ordered, Medicare Administrative Contractors (MACs) and most commercial payers require documentation that the following cessation windows have been met to consider the test result valid and the order medically necessary:

Why Explicit NSAID Negation Matters Independently

Beyond washout documentation, the absence of NSAID use must be affirmatively stated. Silence on NSAID status is not equivalent to negation. When a note says nothing about NSAIDs, a payer reviewer or auditor cannot distinguish:

• Non-NSAID dyspepsia — H. pylori test-and-treat is first-line per ACG 2017 Dyspepsia Guidelines

• NSAID-induced gastropathy — PPI therapy ± NSAID cessation is first-line; H. pylori testing is secondary

• Concurrent NSAID use with H. pylori infection — dual pathology requiring a different management algorithm (NIH: NSAID-H. pylori Interaction)

A properly documented note must include language such as: "Patient denies current or recent NSAID use, including over-the-counter ibuprofen, naproxen, and aspirin (other than low-dose cardioprotective aspirin at 81 mg daily)." This negation statement, when paired with washout documentation, creates the medical necessity scaffold for both the H. pylori test order and any subsequent EGD referral if the test is positive or if alarm features are present.

How Scribing.io handles this: The negation engine uses a ConText-style algorithm — adapted from the NegEx/ConText literature — to detect negation scope in clinician dictation. When the physician says "no Advil, no Aleve, no aspirin," the system tags each medication mention with a negation flag, normalizes brand names to their NSAID RxNorm class, and generates the structured negation statement. Critically, if the clinician fails to address NSAID status entirely, Scribing.io surfaces a real-time prompt: "NSAID exposure status not documented — required for H. pylori test medical necessity per LCD." This is not a passive reminder. It is a hard gate in the note-completion workflow that prevents the order from advancing without the required data.

Scribing.io Clinical Logic: From Denied Claim to First-Pass Payment in Gastritis Workup

Consider this scenario drawn from patterns observed across gastroenterology practices nationwide:

A 46-year-old with 3 months of epigastric pain is scheduled for H. pylori urea breath test, then possible EGD with biopsy. The dictation historically yielded denials: R10.9 (unspecified abdominal pain), no statement about NSAID exposure, and PPI was not held — leading to a false-negative test and a $1,200 EGD denial. With Scribing.io, the live prompt captures: "epigastric pain localizing to antrum," "no NSAID use in last 30 days," and "PPI held ×14 days; no antibiotics/bismuth ×28 days." The note auto-maps to R10.13 and K29.70, inserts LCD-ready language for EGD 43239 if needed, and exports SNOMED-coded antral bodySite via FHIR R4. Prior auth clears in 24 hours, the test is valid, and the claim pays on first pass.

This pattern is not an edge case. It is the modal failure mode for gastritis-related claims. Below is the documentation cascade that produces the denial, followed by the reconstruction through Scribing.io.

The Denial Cascade (Without Scribing.io)

The Clean-Claim Cascade (With Scribing.io) — Step-by-Step Logic Breakdown

With Scribing.io's live-dictation pipeline active, the same clinical encounter produces a fundamentally different documentation artifact. Here is the granular, component-by-component logic:

Physician dictates: "46-year-old male, 3 months of pain in the upper abdomen, points to epigastrium, localizes to the antral region. No Advil, no Aleve, no aspirin other than baby aspirin for his heart. I had him stop his Prilosec two weeks ago. No antibiotics in the last month, no Pepto."

Step 1 — Pain Topography Extraction and Body-Site Encoding:

"Upper abdomen" + "epigastrium" + "antral region" are parsed by the NLP layer. The system identifies three progressively specific anatomic references and maps to the most specific: gastric antrum. Output: R10.13 (Epigastric pain) as the symptom code with SNOMED CT bodySite encoding for gastric antrum (structure of antrum of stomach, SCTID: 362139008). The system does not output R10.9. This is not a preference — it is a hard rule. R10.9 is blocked when any epigastric, periumbilical, or quadrant-specific language is detected.

Step 2 — NSAID Negation Processing:

"No Advil, no Aleve, no aspirin other than baby aspirin" → The negation engine tags ibuprofen (negated), naproxen (negated), and aspirin with qualifier (low-dose cardioprotective, 81 mg, non-NSAID-dose). Structured output: "Patient denies current or recent NSAID use. Low-dose aspirin 81 mg daily for cardiovascular prophylaxis — not at anti-inflammatory dosing." The qualifier matters: FDA distinguishes low-dose aspirin from therapeutic NSAID dosing, and payers follow this distinction.

Step 3 — Washout Window Verification:

• "Stop Prilosec two weeks ago" → Time-normalized to ≥ 14-day PPI washout. ✓ Compliant.

• "No antibiotics in the last month" → ≥ 28-day antibiotic washout. ✓ Compliant.

• "No Pepto" → Bismuth washout confirmed via negation flag. ✓ Compliant.

All three washout gates green. If any gate fails — for example, the physician says "she just finished amoxicillin last week" — Scribing.io fires a clinical decision support alert: "Antibiotic washout not met (28 days required). H. pylori test may yield false-negative. Document clinical rationale to proceed or reschedule test."

Step 4 — Diagnosis Routing Logic:

Pre-claim scrub assigns R10.13 as the symptom code. K29.70 is assigned as the working gastritis diagnosis based on clinical presentation (chronic epigastric pain, non-NSAID, antral localization). B96.81 (Helicobacter pylori as the cause of diseases classified elsewhere) is deferred — it is not assigned until confirmatory testing returns positive. This prevents premature specificity that triggers NCCI claim edits when the test is pending or negative. The routing sequence is: R10.13 → K29.70 → B96.81 (conditional on lab confirmation).

Step 5 — LCD Language Auto-Insertion:

Because the patient has 3 months of refractory epigastric symptoms localized to the gastric antrum without NSAID etiology, the note auto-generates LCD-aligned justification language for EGD 43239:

"Esophagogastroduodenoscopy with biopsy indicated for evaluation of refractory epigastric pain (> 8 weeks duration) localized to the gastric antrum, unresponsive to empiric therapy, in a patient without NSAID exposure, with prior PPI washout completed (≥ 14 days). H. pylori testing to be performed/has been performed. Biopsy for histologic evaluation of antral mucosa to assess for H. pylori colonization, intestinal metaplasia, and dysplasia."

Step 6 — FHIR R4 Structured Export:

The structured note generates interoperable data objects:

• Condition.bodySite → SNOMED CT 362139008 (Structure of antrum of stomach)

• Condition.code → ICD-10 K29.70

• Procedure.reasonCode → R10.13 + K29.70

• Procedure.code → CPT 43239 (EGD with biopsy)

• MedicationStatement → omeprazole, status: stopped, dateAsserted: [14 days prior]

Result: Prior authorization clears within 24 hours. The H. pylori test is clinically valid (washout confirmed). The claim pays on first pass. No appeal. No re-documentation. No 30-day delay.

Technical Reference: ICD-10 Documentation Standards for K29.70 and R10.13

This section provides the coding precision standards that every gastritis note must meet. These are not optional documentation enhancements — they are the minimum thresholds for clean claim submission.

K29.70 — Gastritis, Unspecified, Without Bleeding

K29.70 — Gastritis requires documentation of:

• Absence of hemorrhagic features: The "without bleeding" distinction (K29.70 vs. K29.71) must be explicitly stated. "No hematemesis, no melena, no coffee-ground emesis" creates the negation scaffold. If bleeding is present, K29.71 applies and DRG grouping changes.

• Clinical context supporting gastritis over functional dyspepsia: Per ICD-10-CM Official Guidelines, Section I.A.19, "unspecified" codes (like K29.70) are acceptable when the clinical record does not provide enough specificity for a more specific code — but payers increasingly require documentation that distinguishes inflammatory gastritis from functional dyspepsia (K30). The Scribing.io pipeline inserts language about mucosal inflammation, endoscopic findings, or clinical suspicion to anchor K29.70 as the appropriate code.

• Etiology linkage when known: If H. pylori is confirmed, K29.70 should be paired with B96.81. If autoimmune gastritis is suspected, K29.40 may be more appropriate. Scribing.io's diagnosis routing prevents premature assignment of unspecified etiologic codes before confirmatory evidence exists.

R10.13 — Epigastric Pain

Without bleeding; R10.13 — Epigastric pain is the symptom code that anchors medical necessity for upper GI investigation. Documentation must localize pain to the epigastric region. Acceptable synonyms parsed by Scribing.io include: "upper stomach pain," "pain below the sternum," "substernal abdominal discomfort," and "epigastric tenderness." Unacceptable: "abdominal pain" without qualifier (maps to R10.9), "stomach ache" without localization (maps to R10.9).

Maximum Specificity: How Scribing.io Prevents Code Downgrades

Antral vs. Fundic: Why Body-Site Topography Drives Procedural Authorization

The Anchor Truth of this playbook: To justify medical necessity for H. pylori testing or gastric biopsy, AI logic must document the absence of NSAID use and specifically capture the antral vs. fundic location of pain to support proper procedural coding.

This is not academic nuance. It is a payer audit determinant. Here is why:

• H. pylori has tropism for the gastric antrum. Antral-predominant gastritis is the hallmark of H. pylori infection (Dixon MF et al., Am J Surg Pathol). When a clinician documents antral pain localization, the payer reviewer can trace a direct line from symptom → suspected pathology → test order → biopsy site. This is the medical necessity chain.

• Fundic-predominant gastritis suggests a different etiology. Autoimmune gastritis (K29.40) is fundic/body-predominant. Reactive gastropathy from bile reflux or NSAIDs is often antral but has different treatment implications. Documenting the body-site forces diagnostic specificity and prevents payer confusion about the testing rationale.

• EGD biopsy (43239) authorization requires site-directed justification. A biopsy "of the stomach" is less defensible than a biopsy "of the antral mucosa for H. pylori assessment and histologic evaluation of intestinal metaplasia." Payers reviewing prior-auth requests for 43239 look for this specificity, particularly under the CMS Appropriate Use Criteria (AUC) program.

Scribing.io maps clinician language to SNOMED CT body-site codes in real time:

FHIR R4 Export Architecture: Structured Data That Survives Payer Adjudication

Documentation that exists only as free text in an EHR note is vulnerable to misinterpretation during claim adjudication. Scribing.io converts clinical narrative into HL7 FHIR R4 resources that transmit structured, coded data alongside the claim. The relevant resource mappings for gastritis workup:

This structured export means that when the prior authorization request reaches the payer's automated review system, the system can programmatically verify: diagnosis present (K29.70) → body-site specified (antrum) → symptom code supports upper GI (R10.13) → washout documented (PPI stopped ≥ 14 days) → NSAID negation confirmed → LCD criteria met. Automated approval. No human reviewer queue. No 5-day turnaround.

Diagnosis Routing Sequence: R10.13 → K29.70 → B96.81

One of the most common coding errors in gastritis workup is premature assignment of B96.81 (Helicobacter pylori as the cause of diseases classified elsewhere). This code is an additional code — per ICD-10-CM Official Guidelines, Section I.A.13, it should be used as a secondary code to identify the bacterial agent in diseases classified elsewhere. Assigning B96.81 before H. pylori is confirmed by UBT, stool antigen, or histology creates two problems:

1. NCCI edit triggers: When the test to confirm H. pylori is billed on the same claim as B96.81 (which presumes the diagnosis is established), automated claim scrubbers flag the contradiction. The diagnosis code says "confirmed H. pylori" while the procedure code says "testing for H. pylori."

2. Audit liability: Post-payment audits by RACs and MACs compare diagnosis assignment dates against lab result dates. B96.81 assigned before confirmatory results = unsupported diagnosis = overpayment recoupment.

Scribing.io enforces this sequence through conditional logic:

1. Visit 1 (initial evaluation): R10.13 (symptom) + K29.70 (working diagnosis) → H. pylori UBT ordered

2. Visit 2 (test result review): If UBT positive → K29.70 + B96.81 assigned; eradication therapy initiated. If UBT negative → K29.70 remains; alternative workup (EGD, celiac panel) pursued

3. Visit 3 (EGD if indicated): K29.70 + R10.13 as procedure reason codes; B96.81 added only if antral biopsy shows H. pylori on histology

This temporal gating prevents every premature-code denial pattern documented in OIG audit reports for gastroenterology.

LCD-Ready Language Templates for EGD 43239

The following templates are auto-generated by Scribing.io based on the clinical data captured during dictation. They are designed to satisfy MAC LCD criteria for upper endoscopy medical necessity. Each template includes the documentation elements that payer medical directors confirm they review during prior-authorization adjudication:

Template 1: Refractory Dyspepsia with H. pylori Testing

"EGD with biopsy (CPT 43239) is indicated for evaluation of refractory epigastric pain of [X weeks/months] duration, localized to the [antral/fundic/body] region, unresponsive to [empiric PPI therapy / H2RA therapy / lifestyle modification]. Patient has no current or recent NSAID exposure. PPI was discontinued ≥ 14 days prior to H. pylori testing. [UBT/stool antigen] was [positive/negative/equivocal]. Biopsy is planned for histologic evaluation of [antral/fundic] mucosa to assess for H. pylori colonization, chronic active gastritis, intestinal metaplasia, and dysplasia. No contraindication to endoscopy."

Template 2: Alarm Features Present

"EGD with biopsy (CPT 43239) is indicated for evaluation of epigastric pain with alarm features including [unintentional weight loss of X lbs over Y months / progressive dysphagia / persistent vomiting / GI bleeding / age > 60 with new-onset dyspepsia]. Upper endoscopy is recommended for direct mucosal visualization and tissue sampling per ACG guidelines. Biopsy targets: [antral mucosa for H. pylori and intestinal metaplasia / esophageal mucosa for eosinophilic esophagitis / duodenal mucosa for celiac disease]."

Template 3: Post-Eradication Confirmation

"EGD with biopsy (CPT 43239) is indicated for confirmation of H. pylori eradication in a patient with previously confirmed H. pylori gastritis (B96.81) who completed [triple/quadruple/bismuth-based] eradication therapy on [date]. UBT performed ≥ 4 weeks post-treatment completion and ≥ 14 days off PPI was [positive/negative/equivocal]. Endoscopic biopsy is required due to [concern for treatment failure / persistent symptoms despite negative UBT / need for culture and antibiotic sensitivity testing given prior eradication failure]."

Gastritis/H. pylori Denial-Prevention Pack

See our Gastritis/H. pylori denial-prevention pack: real-time LCD checks, FHIR R4 body-site export (antral vs. fundic), and negation-aware NSAID/PPI washout capture — live in your EHR. Request your Scribing.io demo and run the 46-year-old epigastric pain scenario through the system yourself. Watch it block R10.9, fire the NSAID prompt, verify washout windows, route diagnosis sequencing, insert LCD language, and export structured FHIR R4 — in under 90 seconds of dictation.

Every denied gastritis claim has the same root cause: the note contained the clinical reasoning but not the documentation structure. Scribing.io's pipeline does not change how you practice medicine. It changes how your notes survive payer adjudication.

→ Scribing.io: Documentation infrastructure for gastroenterology